Long Term Outcomes for Basal Cell Carcinoma Treated with Vismodegib Extended Alternate Day Dosing
نویسندگان
چکیده
منابع مشابه
Vismodegib (erivedge) for advanced Basal cell carcinoma.
Vismodegib (Erivedge) for advanced basal cell carcinoma.
متن کاملTargeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a trea...
متن کاملVismodegib for periocular and orbital basal cell carcinoma.
IMPORTANCE Basal cell carcinoma (BCC) represents 90% of malignant eyelid tumors and is locally invasive and destructive, if left untreated. OBJECTIVE To assess the feasibility of using vismodegib for periocular and orbital BCC based on its efficacy and tolerability. DESIGN, SETTING, AND PARTICIPANTS In this prospective observational case series, consecutive patients with periocular or orbit...
متن کاملConcurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
IMPORTANCE Vismodegib is a targeted agent recently approved for treating patients who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integrated into existing therapy for advanced BCC as it becomes increasingly used. Improved understanding of how vismodegib interacts with other treatment modalities, including radiotherapy, would help optimize multidiscip...
متن کاملInvestigational agents in metastatic basal cell carcinoma: focus on vismodegib.
Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bio-available Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the United States on January 2012. This signaling pathway is involved in the carcinogenesis of several ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: SKIN The Journal of Cutaneous Medicine
سال: 2019
ISSN: 2574-1624
DOI: 10.25251/skin.3.2.32